Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled “Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial”, the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208 […]
Author: Ken Dropiewski
Jeffrey J. Popma, M.D. to Join Medtronic as Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart Businesses
DUBLIN, May 18, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced Jeffrey J. Popma, M.D., professor of medicine at Harvard Medical School and director of interventional cardiology at Beth Israel Deaconess Medical Center in Boston, will join Medtronic as Vice President and Chief Medical Officer […]
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced the appointment of Tushar Shah, M.D., to the newly created position of Chief Medical Officer. In […]
Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction BASKING RIDGE, N.J., May 14, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, […]
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
SAN CARLOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2020 and filed its quarterly report on Form 10-Q for the three months ended March […]
Surmodics Names Gordon Weber as Senior Vice President of Legal, General Counsel and Secretary
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Gordon Weber has joined Surmodics as Senior Vice President of Legal, General Counsel and Secretary effective May 13, 2020. “Gordon is a seasoned executive with over […]
Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., May 14, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2020 and provided a clinical and corporate update. “While the NODE-301 trial of etripamil for patients with paroxysmal supraventricular […]
Clinical Study Shows Cardiologs’ AI Reduces The False Positive Burden Of Implantable Loop Recorders By Almost 70%
Data presented at HRS 2020 shows Cardiologs’ AI-system successfully eliminates more than two-thirds of atrial fibrillation false positives from ILR reports, alleviating the clinical burden associated with remote monitoring PARIS and BOSTON, May 14, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) for cardiac diagnostics, today in partnership with the Valley Health […]
VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in Prespecified and Post Hoc Analyses of Landmark REDUCE-IT® Study
First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses Results of prespecified tertiary endpoint analyses consistent across different types of coronary revascularization procedures, including urgent, emergent, and elective interventions Percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) […]
Acarix AB (publ) publishes Interim Report, January – March 2020
Press release (MAR) Malmö, May 14, 2020 Acarix AB (publ) publishes Interim Report, January – March 2020 Continued focus on strategic key priorities During the quarter we have kept focus on our priorities along with managing the impact from the global Covid-19 situation. We have been in continued dialogue with […]



